Dr. Thomas R. Williams, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 885
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NC license 9501152
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Catawba Valley Medical Center Hickory, NC
Medical groups
- Graystone Ophthalmology Associates, P.a. (19 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 885
- Services billed
- 55,899
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 21,360 | 108 |
| Injection, aflibercept, 1 mg | 2,058 | 307 |
| Imaging of retina | 1,836 | 811 |
| Injection of drug into eye | 1,227 | 415 |
| Established patient office or other outpatient visit, 20-29 minutes | 792 | 514 |
| Established patient office or other outpatient visit, 30-39 minutes | 548 | 507 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 273 | 15 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 140 | 137 |
| Photography of the retina | 121 | 118 |
| New patient office or other outpatient visit, 45-59 minutes | 95 | 95 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brimonidine Tartrate Other prescribers in Hickory, NC | 44 |
| Prednisolone Acetate Other prescribers in Hickory, NC | 37 |
| Timolol Maleate Other prescribers in Hickory, NC | 25 |
| Latanoprost Other prescribers in Hickory, NC | 18 |
| Diazepam Other prescribers in Hickory, NC | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 19 payments worth $468 in total to this clinician.
| Genentech USA, Inc. | $90.12 |
|---|---|
| Ani Pharmaceuticals, Inc. | $86.59 |
| Apellis Pharmaceuticals, Inc. | $64.97 |
| Notal Vision, Inc. | $52.82 |
| AbbVie Inc. | $49.55 |
| Regeneron Healthcare Solutions, Inc. | $44.98 |
| Johnson & Johnson Surgical Vision, Inc. | $33.33 |
| Astellas Pharma US Inc | $26.15 |
| Food and Beverage | $468 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $139,353 in research payments for these studies, mostly to the institutions running them.
- Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - NRICH
Notal Vision, Inc. - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.